Copyright © 2022 Binhui Bio All Rights Reserved
E.ICP B. No.16007335Legal Terms
Partners
Four
PlatformsThrough the accumulation of technology, talents, and management experience gained over the last ten years in the R&D and industrialization of innovative anti-tumor drugs, Binhui Bio has developed a mature technical service platform for viral vectors, nucleic acid drugs, protein drugs, and cell therapies.
Viral Vector Platform
Nucleic Acid Platform
Protein Platform
Cell Therapy Platform
Binhui's Viral Vector Platform
The highly scalable oHSV2-based platform1)Deletion of neurotoxic factor ICP34.5, promote selective viral replication in tumor cells, enhance safety.
2)Deletion of immune suppressive gene ICP47, promote antigen presentation and viral replication, enhance anti-tumor efficacy.
3)Insert GM-CSF, to induce stronger, durable and specific anti-tumor immune responses.
Viral Vector Platform Progress
Candidates
Indication
Pre-clinical
IND
Doses Escalation (Phase I)
Doses Extension (Phase II)
Protal Study (Phase III)
Melanoma
Glioma
Colorectal
Other indications
Melanoma
Colorectal
Sarcoma
Solid Tumor(IIT)
Solid Tumor
Solid Tumor
BH-RACE platform of nucleic acid drug
Product process
S-protein trimer mRNA vaccine
Monkeypox vaccine
Rabies vaccine
Neo-antigen tumor vaccines
Heterologous tumor mRNA vaccines
In vivo CAR-T
In vivo CAR-NK
Nucleic Acid Platform Progress
Candidates
Indication
Pre-clinical
IND
Doses Escalation (Phase I)
Doses Extension (Phase II)
Protal Study (Phase III)
Solid Tumor
Vaccines, Muscle Spasms, Wrinkle Reduction
Unique protein purification process
Protein Platform Progress
Candidates
Indication
Pre-clinical
IND
Doses Escalation (Phase I)
Doses Extension (Phase II)
Protal Study (Phase III)
/
Vaccines for Human and Veterinary
Cell Therapy Platform Progress
Candidates
Indication
Pre-clinical
IND
Doses Escalation (Phase I)
Doses Extension (Phase II)
Protal Study (Phase III)
Malignant Pleural and Peritoneal Effusion(IIT)
Malignant Pleural and Peritoneal Effusion